A PRIVAÇÃO ANDROGÊNICA DE LONGO PRAZO MODULA A REATIVIDADE VASCULAR POR VIAS DEPENDENTES DE ALDOSTERONA E ANGIOTENSINA II

Detalhes bibliográficos
Autor(a) principal: Costa, Anna Karolina Nascimento
Data de Publicação: 2022
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
Texto Completo: http://repositorio.ufes.br/handle/10/16980
Resumo: Testosterone is a vasoactive hormone, which acts by genomic and non-genomic mechanisms. Acutely, it may have endothelium-dependent vasodilatory actions. However, the long-term modulation of testosterone on the regulation of vascular tone remains unclear. The hypothesis of this study is that, in the long term, testosterone participates in the vascular reactivity regulation, dependent on the renin-angiotensin- aldosterone system. Wistar rats (N=128), at 12 weeks of age, were divided into male Control (SHAM) and orchiectomy surgery (OQT), treated for 3 months with losartan, an angiotensin II receptor blocker (SHAM+LOS and OQT+ LOS), 15 mg/kg, s.c); spironolactone (SHAM+SPI and OQT+SPI, 80 mg/kg, gavage), mineralocorticoid receptor antagonist and apocynin, NADPH oxidase inhibitor (SHAM+APO and OQT+APO, 30 mg/kg, drinking water), Vascular reactivity was analysed in isolated aortic rings, as the percentage of response to KCl (75 mM), superfused with modified Krebs pH 7.4, 36.5oC. The presence of vascular presence was observed in vitro as curves-response to phenylephrine (10-11 to 10-3 M) and absence of: L-NAME, 100 μM; indomethacin (INDO, 10 μM) and endothelium-denuded rings (E-). Plasma lipid peroxidation was measured using the TBARS technique. (CEUA-UFES 017/2020). Results were expressed as mean ± SEM and using Student's t test, analysis of variance (ANOVA), one way. The OQT groups, untreated and OQT treated with APO and LOS, had lower body weight at the end of the 3 months (SHAM 231 ± 11g; OQT= 158,4 ± 13,0g*; OQT+APO 208,3 ± 15,4g; OQT+LOS 156,0 ± 23,0g *p<0,05). The Rmax for phenylephrine was the same between the SHAM and OQT groups. Treatments for 3 months with LOS and APO did not change Rmax to phenylephrine. However, LOS treatment reduced the pD2 of the OQT group (log EC50: OQT= -6.240 ± 0.15 vs OQT+LOS= -7.218 ± 0.23 *p<0.01). Inhibition of MR receptors with spironolactone determined a lower maximal contraction to phenylephrine in the OQT group than in the SHAM, suggesting that this pathway could be testosterone dependent. (SHAM+SPI =120.4 ± 7.56% n=10 vs OQT+SPI= 93.3 ± 10.2% n=10; *p<0.05). Phenylephrine reactivity increased in the presence of L-NAME and in the absence of E, similarly between the groups. Inhibition of the COX pathway with indomethacin determined a reduction in Rmax in both groups (Rmax SHAM= 118.3 ± 8.04 vs SHAM+INDO = 56.27 ± 6.61, p <0.01 and OQT= 119.8 ± 8.41 vs OQT+INDO= 72.64 ± 9.34, p<0.01). There was no difference in reactivity between the groups incubated with indomethacin (SHAM+INDO and OQT+INDO). There was a reduction in RMax, in the presence of indomethacin, only in the OQT+SPI group. This result suggests the participation of aldosterone in the COX activation pathway, possibly of a vasoconstrictor, since in the SHAM+SPI group, indomethacin reduced the maximum contraction (Rmax: SHAM+SPI = 120.4 ± 7.56; OQT+ SPI= 93.28 ± 10.18; SHAM+SPI+INDO = 89.99 ± 8.45; OQT+SPI+INDO = 74.15 ± 7.92, * p <0.05). Endothelial NO bioavaliability seems to have been modified in the group treated with losartan, especially in the OQT+LOS- LN group, suggesting the importance of the testosterone pathway in the production of NO mediated by angiotensin II receptors. These data suggest that testosterone participates in the production of NO mediated by angio II, because when we remove the production of NO, through the LN, in the OQT group, there was a reduction in Rmax in relation to its control. Is suggests the importance of testosterone in the contractile response. mediated by the AT1 angiotensin receptor (Rmax: SHAM+LOS = 127.5 ± 5.63; OQT+LOS = 135.6 ± 4.74; SHAM+LOS LN = 183.4 ± 10.50; OQT+LOS LN = 151.8 ± 8.311; * p<0.05). The effects of treatment with the angiotensin II inhibitor, losartan, on rings without endothelium, showed that the endothelium injury caused an increase in the response to phenylephrine in the SHAM group. However, there was no difference between the OQT+LOS E- and OQT+LOS CT groups, suggesting a vasoconstrictor positive modulation that depends on the presence of angiotensin II. These data suggest that testosterone participates in the production of NO mediated by angio II, because when we remove the production of NO, through the LN, in the castrated group there is a reduction in Rmax in relation to its control, suggesting the importance of testosterone in the contractile response. mediated by the AT1 angiotensin receptor (Rmax: SHAM+LOS = 127.5 ± 5.63; OQT+LOS = 135.6 ± 4.74; SHAM+LOS LN = 183.4 ± 10.50; OQT+LOS LN = 151.8 ± 8.311; * p<0.05). The effects of treatment with the angiotensin II inhibitor, losartan, on rings without endothelium, showed that the endothelium injury caused an increase in the response to phenylephrine in the SHAM group. However, there was no difference between the OQT+LOS E- and OQT+LOS CT groups, suggesting a vasoconstrictor positive modulation that depends on the presence of angiotensin II. Orchidectomy modified the endothelium-dependent response during treatment with losartam (Rmax: SHAM+LOS = 127.5 ± 5.63; OQT+LOS = 135.6 ± 4.74; SHAM+LOS E- = 217.3 ± 217.3 ± 26.77; OQT+LOS E- = 145.3 ± 7.90. * p<0.05). In conclusion, the set of these results suggest the long term participation of testosterone and aldosterone in the modulation of vascular contraction induced by phenylephrine.
id UFES_bdec415813936bac2635579bc6d8e8c7
oai_identifier_str oai:repositorio.ufes.br:10/16980
network_acronym_str UFES
network_name_str Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
repository_id_str 2108
spelling Stefanon, Ivanitahttps://orcid.org/0000-0003-2638-5183http://lattes.cnpq.br/8456612999765726Costa, Anna Karolina Nascimentohttps://orcid.org/http://lattes.cnpq.br/0575590472541198Bissoli, Nazare Souzahttps://orcid.org/http://lattes.cnpq.br/8865368585732583Davel, Ana Paula Coutohttps://orcid.org/http://lattes.cnpq.br/2024-05-30T01:42:00Z2024-05-30T01:42:00Z2022-08-31Testosterone is a vasoactive hormone, which acts by genomic and non-genomic mechanisms. Acutely, it may have endothelium-dependent vasodilatory actions. However, the long-term modulation of testosterone on the regulation of vascular tone remains unclear. The hypothesis of this study is that, in the long term, testosterone participates in the vascular reactivity regulation, dependent on the renin-angiotensin- aldosterone system. Wistar rats (N=128), at 12 weeks of age, were divided into male Control (SHAM) and orchiectomy surgery (OQT), treated for 3 months with losartan, an angiotensin II receptor blocker (SHAM+LOS and OQT+ LOS), 15 mg/kg, s.c); spironolactone (SHAM+SPI and OQT+SPI, 80 mg/kg, gavage), mineralocorticoid receptor antagonist and apocynin, NADPH oxidase inhibitor (SHAM+APO and OQT+APO, 30 mg/kg, drinking water), Vascular reactivity was analysed in isolated aortic rings, as the percentage of response to KCl (75 mM), superfused with modified Krebs pH 7.4, 36.5oC. The presence of vascular presence was observed in vitro as curves-response to phenylephrine (10-11 to 10-3 M) and absence of: L-NAME, 100 μM; indomethacin (INDO, 10 μM) and endothelium-denuded rings (E-). Plasma lipid peroxidation was measured using the TBARS technique. (CEUA-UFES 017/2020). Results were expressed as mean ± SEM and using Student's t test, analysis of variance (ANOVA), one way. The OQT groups, untreated and OQT treated with APO and LOS, had lower body weight at the end of the 3 months (SHAM 231 ± 11g; OQT= 158,4 ± 13,0g*; OQT+APO 208,3 ± 15,4g; OQT+LOS 156,0 ± 23,0g *p<0,05). The Rmax for phenylephrine was the same between the SHAM and OQT groups. Treatments for 3 months with LOS and APO did not change Rmax to phenylephrine. However, LOS treatment reduced the pD2 of the OQT group (log EC50: OQT= -6.240 ± 0.15 vs OQT+LOS= -7.218 ± 0.23 *p<0.01). Inhibition of MR receptors with spironolactone determined a lower maximal contraction to phenylephrine in the OQT group than in the SHAM, suggesting that this pathway could be testosterone dependent. (SHAM+SPI =120.4 ± 7.56% n=10 vs OQT+SPI= 93.3 ± 10.2% n=10; *p<0.05). Phenylephrine reactivity increased in the presence of L-NAME and in the absence of E, similarly between the groups. Inhibition of the COX pathway with indomethacin determined a reduction in Rmax in both groups (Rmax SHAM= 118.3 ± 8.04 vs SHAM+INDO = 56.27 ± 6.61, p <0.01 and OQT= 119.8 ± 8.41 vs OQT+INDO= 72.64 ± 9.34, p<0.01). There was no difference in reactivity between the groups incubated with indomethacin (SHAM+INDO and OQT+INDO). There was a reduction in RMax, in the presence of indomethacin, only in the OQT+SPI group. This result suggests the participation of aldosterone in the COX activation pathway, possibly of a vasoconstrictor, since in the SHAM+SPI group, indomethacin reduced the maximum contraction (Rmax: SHAM+SPI = 120.4 ± 7.56; OQT+ SPI= 93.28 ± 10.18; SHAM+SPI+INDO = 89.99 ± 8.45; OQT+SPI+INDO = 74.15 ± 7.92, * p <0.05). Endothelial NO bioavaliability seems to have been modified in the group treated with losartan, especially in the OQT+LOS- LN group, suggesting the importance of the testosterone pathway in the production of NO mediated by angiotensin II receptors. These data suggest that testosterone participates in the production of NO mediated by angio II, because when we remove the production of NO, through the LN, in the OQT group, there was a reduction in Rmax in relation to its control. Is suggests the importance of testosterone in the contractile response. mediated by the AT1 angiotensin receptor (Rmax: SHAM+LOS = 127.5 ± 5.63; OQT+LOS = 135.6 ± 4.74; SHAM+LOS LN = 183.4 ± 10.50; OQT+LOS LN = 151.8 ± 8.311; * p<0.05). The effects of treatment with the angiotensin II inhibitor, losartan, on rings without endothelium, showed that the endothelium injury caused an increase in the response to phenylephrine in the SHAM group. However, there was no difference between the OQT+LOS E- and OQT+LOS CT groups, suggesting a vasoconstrictor positive modulation that depends on the presence of angiotensin II. These data suggest that testosterone participates in the production of NO mediated by angio II, because when we remove the production of NO, through the LN, in the castrated group there is a reduction in Rmax in relation to its control, suggesting the importance of testosterone in the contractile response. mediated by the AT1 angiotensin receptor (Rmax: SHAM+LOS = 127.5 ± 5.63; OQT+LOS = 135.6 ± 4.74; SHAM+LOS LN = 183.4 ± 10.50; OQT+LOS LN = 151.8 ± 8.311; * p<0.05). The effects of treatment with the angiotensin II inhibitor, losartan, on rings without endothelium, showed that the endothelium injury caused an increase in the response to phenylephrine in the SHAM group. However, there was no difference between the OQT+LOS E- and OQT+LOS CT groups, suggesting a vasoconstrictor positive modulation that depends on the presence of angiotensin II. Orchidectomy modified the endothelium-dependent response during treatment with losartam (Rmax: SHAM+LOS = 127.5 ± 5.63; OQT+LOS = 135.6 ± 4.74; SHAM+LOS E- = 217.3 ± 217.3 ± 26.77; OQT+LOS E- = 145.3 ± 7.90. * p<0.05). In conclusion, the set of these results suggest the long term participation of testosterone and aldosterone in the modulation of vascular contraction induced by phenylephrine.A testosterona é um hormônio vasoativo, que age por mecanismos genômicos e não genômicos. Agudamente, pode apresentar ações vasodilatadoras dependente do endotelio. Entretanto, ainda não está clara, a modulação, em longo prazo, da testosterona, sobre a regulação do tônus vascular. A hipótese desse estudo é de que, a testosterona participa, em longo prazo, da regulação da reatividade vascular, por uma via dependente do sistema renina angiotensina aldosterona. Ratos machos Wistar (N=128), com 12 semanas de idade foram divididos em Controle (SHAM) e cirurgia de orquidectomia (OQT), tratados durante 3 meses com losartan, bloqueador de receptor para angiotensina II (SHAM+LOS e OQT+LOS, 15 mg/kg, s.c); espironolactona (SHAM+SPI e OQT+SPI, 80 mg/kg, gavagem), antagonista de receptor para mineralocorticoide e Apocinina, antioxidante inibidor da NADPH oxidase (SHAM+APO e OQT+APO, 30 mg/kg, água de beber), A reatividade vascular foi avaliada em anéis isolados de aorta torácica, como o percentual de resposta ao KCl (75 mM), nutridos com solução de Krebs modificado, pH 7,4, 36,5oC. A reatividade vascular foi avaliada in vitro como curvas concentração-resposta à fenilefrina (10-11 a 10-3 M) na presença e ausência de: L-NAME, 100 μM; indometacina (INDO, 10 μM), e anéis sem endotélio (E-). A peroxidação lipídica plasmática foi mensurada usando a técnica de TBARS. (CEUA-UFES 017/2020). Os resultados foram expressos como média ± EPM e comparados usando teste t de student, análise de variância (ANOVA), uma via. Os grupos OQT, não tratados e os tratados com APO e LOS, apresentaram menor ganho de peso corporal ao final dos 3 meses (SHAM 231 ± 11g; OQT= 158,4 ± 13,0g*; OQT+APO 208,3 ± 15,4g; OQT+LOS 156,0 ± 23,0g *p<0,05). A Rmax a fenilefrina foi igual entre os grupos SHAM e OQT. Os tratamentos durante 3 meses com LOS e APO não modificaram Rmax a fenilefrina. Entretanto, o tratamento com LOS reduziu a pD2 do grupo OQT (log EC50: OQT= -6,240 ± 0,15 vs OQT+LOS= - 7,218 ± 0,23 *p<0.01). A inibição dos receptores de MR, com espironolactona, determinou uma menor contração máxima à fenilefrina no grupo OQT do que no SHAM, sugerindo então que esta via poderia ser dependente da testosterona. (SHAM+SPI =120,4 ± 7,56 % n=10 vs OQT+SPI= 93,3 ± 10,2 % n=10; *p<0,05). A reatividade à fenilefrina aumentou, na presença de L-NAME, e na ausência de E, de maneira semelhante entre os grupos. A inibição da via da COX, com indometacina, determinou redução da Rmax em ambos os grupos (Rmax SHAM= 118,3 ± 8,04 vs SHAM+INDO = 56,27 ± 6,61, p <0,01 e OQT= 119,8 ± 8,41 vs OQT+INDO= 72,64 ± 9,34, p<0,01). Não houve diferença de reatividade entre os grupos incubados com indometacina (SHAM+INDO e OQT+INDO). Houve redução de RMax, na presença de indometacina, apenas no grupo OQT+SPI. Este resultado sugere a participação da aldosterona na via de ativação da COX, possivelmente de um vasoconstrictor, já que no grupo SHAM+SPI, a indometacina reduziu a contração máxima (Rmax: SHAM+SPI = 120,4 ± 7,56; OQT+SPI= 93,28 ± 10,18; SHAM+SPI+INDO = 89,99 ± 8,45; OQT+SPI+INDO = 74,15 ± 7,92, * p <0,05). A produção de NO endotelial parece ter sido modificada no grupo tratado com losartan, sobretudo no grupo OQT+LOS-LN, sugerindo a importância da via da testosterona na produção de NO mediada pelos receptores de angiotensina II. Estes dados sugerem que a testosterona participa da produção de NO mediada pela angio II, pois quando retiramos a produção de NO, através do LN, no grupo castrado há uma redução da Rmáx em relação ao seu controle, sugerindo a importância da testosterona na resposta contrátil mediada pelo receptor de angiotensina AT1 (Rmáx: SHAM+LOS = 127,5 ± 5,63; OQT+LOS = 135,6 ± 4,74; SHAM+LOS LN = 183,4 ± 10,50; OQT+LOS LN = 151,8 ± 8,311; * p<0,05). Os efeitos do tratamento com inibidor da angiotensina II, losartan, em anéis sem endotélio, mostraram que a lesão do endotélio provocou o aumento da resposta à fenilefrina no grupo SHAM. Entretanto, não houve diferença entre os grupos OQT+LOS E- e OQT+LOS CT, sugerindo uma modulação positiva vasoconstrictora que depende da presença de angiotensina II. A castração modificou a resposta dependente do endotélio durante o tratamento com losartam (Rmáx: SHAM+LOS = 127,5 ± 5,63; OQT+LOS = 135,6 ± 4,74; SHAM+LOS E- = 217,3 ± 26,77; OQT+LOS E- = 145,3 ± 7,90. * p<0,05). O conjunto desses resultados sugerem a participação da testosterona e aldosterona, na modulação de longo prazo, da contração vascular, induzida pela fenilefrina.Texthttp://repositorio.ufes.br/handle/10/16980porUniversidade Federal do Espírito SantoMestrado em Ciências FisiológicasPrograma de Pós-Graduação em Ciências FisiológicasUFESBRCentro de Ciências da Saúdesubject.br-rjbnFisiologiaTestosteronaAngiotensina IIReatividade VascularAldosterona, Hormonios Sexuais MasculinosEndotelio VascularA PRIVAÇÃO ANDROGÊNICA DE LONGO PRAZO MODULA A REATIVIDADE VASCULAR POR VIAS DEPENDENTES DE ALDOSTERONA E ANGIOTENSINA IItitle.alternativeinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)instname:Universidade Federal do Espírito Santo (UFES)instacron:UFESORIGINALAnnaKarolinaNascimentoCosta-2022-trabalho.pdfapplication/pdf3595568http://repositorio.ufes.br/bitstreams/8ebf2879-a972-4c3a-897c-a9f6d43e9c52/download4ffcf98b029a8ecf99ae5b53a6f77483MD5110/169802024-08-08 10:54:38.484oai:repositorio.ufes.br:10/16980http://repositorio.ufes.brRepositório InstitucionalPUBhttp://repositorio.ufes.br/oai/requestopendoar:21082024-10-15T17:57:39.656940Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) - Universidade Federal do Espírito Santo (UFES)false
dc.title.none.fl_str_mv A PRIVAÇÃO ANDROGÊNICA DE LONGO PRAZO MODULA A REATIVIDADE VASCULAR POR VIAS DEPENDENTES DE ALDOSTERONA E ANGIOTENSINA II
dc.title.alternative.none.fl_str_mv title.alternative
title A PRIVAÇÃO ANDROGÊNICA DE LONGO PRAZO MODULA A REATIVIDADE VASCULAR POR VIAS DEPENDENTES DE ALDOSTERONA E ANGIOTENSINA II
spellingShingle A PRIVAÇÃO ANDROGÊNICA DE LONGO PRAZO MODULA A REATIVIDADE VASCULAR POR VIAS DEPENDENTES DE ALDOSTERONA E ANGIOTENSINA II
Costa, Anna Karolina Nascimento
Fisiologia
Testosterona
Angiotensina II
Reatividade Vascular
Aldosterona, Hormonios Sexuais Masculinos
Endotelio Vascular
subject.br-rjbn
title_short A PRIVAÇÃO ANDROGÊNICA DE LONGO PRAZO MODULA A REATIVIDADE VASCULAR POR VIAS DEPENDENTES DE ALDOSTERONA E ANGIOTENSINA II
title_full A PRIVAÇÃO ANDROGÊNICA DE LONGO PRAZO MODULA A REATIVIDADE VASCULAR POR VIAS DEPENDENTES DE ALDOSTERONA E ANGIOTENSINA II
title_fullStr A PRIVAÇÃO ANDROGÊNICA DE LONGO PRAZO MODULA A REATIVIDADE VASCULAR POR VIAS DEPENDENTES DE ALDOSTERONA E ANGIOTENSINA II
title_full_unstemmed A PRIVAÇÃO ANDROGÊNICA DE LONGO PRAZO MODULA A REATIVIDADE VASCULAR POR VIAS DEPENDENTES DE ALDOSTERONA E ANGIOTENSINA II
title_sort A PRIVAÇÃO ANDROGÊNICA DE LONGO PRAZO MODULA A REATIVIDADE VASCULAR POR VIAS DEPENDENTES DE ALDOSTERONA E ANGIOTENSINA II
author Costa, Anna Karolina Nascimento
author_facet Costa, Anna Karolina Nascimento
author_role author
dc.contributor.authorID.none.fl_str_mv https://orcid.org/
dc.contributor.authorLattes.none.fl_str_mv http://lattes.cnpq.br/0575590472541198
dc.contributor.advisor1.fl_str_mv Stefanon, Ivanita
dc.contributor.advisor1ID.fl_str_mv https://orcid.org/0000-0003-2638-5183
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/8456612999765726
dc.contributor.author.fl_str_mv Costa, Anna Karolina Nascimento
dc.contributor.referee1.fl_str_mv Bissoli, Nazare Souza
dc.contributor.referee1ID.fl_str_mv https://orcid.org/
dc.contributor.referee1Lattes.fl_str_mv http://lattes.cnpq.br/8865368585732583
dc.contributor.referee2.fl_str_mv Davel, Ana Paula Couto
dc.contributor.referee2ID.fl_str_mv https://orcid.org/
dc.contributor.referee2Lattes.fl_str_mv http://lattes.cnpq.br/
contributor_str_mv Stefanon, Ivanita
Bissoli, Nazare Souza
Davel, Ana Paula Couto
dc.subject.cnpq.fl_str_mv Fisiologia
topic Fisiologia
Testosterona
Angiotensina II
Reatividade Vascular
Aldosterona, Hormonios Sexuais Masculinos
Endotelio Vascular
subject.br-rjbn
dc.subject.por.fl_str_mv Testosterona
Angiotensina II
Reatividade Vascular
Aldosterona, Hormonios Sexuais Masculinos
Endotelio Vascular
dc.subject.br-rjbn.none.fl_str_mv subject.br-rjbn
description Testosterone is a vasoactive hormone, which acts by genomic and non-genomic mechanisms. Acutely, it may have endothelium-dependent vasodilatory actions. However, the long-term modulation of testosterone on the regulation of vascular tone remains unclear. The hypothesis of this study is that, in the long term, testosterone participates in the vascular reactivity regulation, dependent on the renin-angiotensin- aldosterone system. Wistar rats (N=128), at 12 weeks of age, were divided into male Control (SHAM) and orchiectomy surgery (OQT), treated for 3 months with losartan, an angiotensin II receptor blocker (SHAM+LOS and OQT+ LOS), 15 mg/kg, s.c); spironolactone (SHAM+SPI and OQT+SPI, 80 mg/kg, gavage), mineralocorticoid receptor antagonist and apocynin, NADPH oxidase inhibitor (SHAM+APO and OQT+APO, 30 mg/kg, drinking water), Vascular reactivity was analysed in isolated aortic rings, as the percentage of response to KCl (75 mM), superfused with modified Krebs pH 7.4, 36.5oC. The presence of vascular presence was observed in vitro as curves-response to phenylephrine (10-11 to 10-3 M) and absence of: L-NAME, 100 μM; indomethacin (INDO, 10 μM) and endothelium-denuded rings (E-). Plasma lipid peroxidation was measured using the TBARS technique. (CEUA-UFES 017/2020). Results were expressed as mean ± SEM and using Student's t test, analysis of variance (ANOVA), one way. The OQT groups, untreated and OQT treated with APO and LOS, had lower body weight at the end of the 3 months (SHAM 231 ± 11g; OQT= 158,4 ± 13,0g*; OQT+APO 208,3 ± 15,4g; OQT+LOS 156,0 ± 23,0g *p<0,05). The Rmax for phenylephrine was the same between the SHAM and OQT groups. Treatments for 3 months with LOS and APO did not change Rmax to phenylephrine. However, LOS treatment reduced the pD2 of the OQT group (log EC50: OQT= -6.240 ± 0.15 vs OQT+LOS= -7.218 ± 0.23 *p<0.01). Inhibition of MR receptors with spironolactone determined a lower maximal contraction to phenylephrine in the OQT group than in the SHAM, suggesting that this pathway could be testosterone dependent. (SHAM+SPI =120.4 ± 7.56% n=10 vs OQT+SPI= 93.3 ± 10.2% n=10; *p<0.05). Phenylephrine reactivity increased in the presence of L-NAME and in the absence of E, similarly between the groups. Inhibition of the COX pathway with indomethacin determined a reduction in Rmax in both groups (Rmax SHAM= 118.3 ± 8.04 vs SHAM+INDO = 56.27 ± 6.61, p <0.01 and OQT= 119.8 ± 8.41 vs OQT+INDO= 72.64 ± 9.34, p<0.01). There was no difference in reactivity between the groups incubated with indomethacin (SHAM+INDO and OQT+INDO). There was a reduction in RMax, in the presence of indomethacin, only in the OQT+SPI group. This result suggests the participation of aldosterone in the COX activation pathway, possibly of a vasoconstrictor, since in the SHAM+SPI group, indomethacin reduced the maximum contraction (Rmax: SHAM+SPI = 120.4 ± 7.56; OQT+ SPI= 93.28 ± 10.18; SHAM+SPI+INDO = 89.99 ± 8.45; OQT+SPI+INDO = 74.15 ± 7.92, * p <0.05). Endothelial NO bioavaliability seems to have been modified in the group treated with losartan, especially in the OQT+LOS- LN group, suggesting the importance of the testosterone pathway in the production of NO mediated by angiotensin II receptors. These data suggest that testosterone participates in the production of NO mediated by angio II, because when we remove the production of NO, through the LN, in the OQT group, there was a reduction in Rmax in relation to its control. Is suggests the importance of testosterone in the contractile response. mediated by the AT1 angiotensin receptor (Rmax: SHAM+LOS = 127.5 ± 5.63; OQT+LOS = 135.6 ± 4.74; SHAM+LOS LN = 183.4 ± 10.50; OQT+LOS LN = 151.8 ± 8.311; * p<0.05). The effects of treatment with the angiotensin II inhibitor, losartan, on rings without endothelium, showed that the endothelium injury caused an increase in the response to phenylephrine in the SHAM group. However, there was no difference between the OQT+LOS E- and OQT+LOS CT groups, suggesting a vasoconstrictor positive modulation that depends on the presence of angiotensin II. These data suggest that testosterone participates in the production of NO mediated by angio II, because when we remove the production of NO, through the LN, in the castrated group there is a reduction in Rmax in relation to its control, suggesting the importance of testosterone in the contractile response. mediated by the AT1 angiotensin receptor (Rmax: SHAM+LOS = 127.5 ± 5.63; OQT+LOS = 135.6 ± 4.74; SHAM+LOS LN = 183.4 ± 10.50; OQT+LOS LN = 151.8 ± 8.311; * p<0.05). The effects of treatment with the angiotensin II inhibitor, losartan, on rings without endothelium, showed that the endothelium injury caused an increase in the response to phenylephrine in the SHAM group. However, there was no difference between the OQT+LOS E- and OQT+LOS CT groups, suggesting a vasoconstrictor positive modulation that depends on the presence of angiotensin II. Orchidectomy modified the endothelium-dependent response during treatment with losartam (Rmax: SHAM+LOS = 127.5 ± 5.63; OQT+LOS = 135.6 ± 4.74; SHAM+LOS E- = 217.3 ± 217.3 ± 26.77; OQT+LOS E- = 145.3 ± 7.90. * p<0.05). In conclusion, the set of these results suggest the long term participation of testosterone and aldosterone in the modulation of vascular contraction induced by phenylephrine.
publishDate 2022
dc.date.issued.fl_str_mv 2022-08-31
dc.date.accessioned.fl_str_mv 2024-05-30T01:42:00Z
dc.date.available.fl_str_mv 2024-05-30T01:42:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufes.br/handle/10/16980
url http://repositorio.ufes.br/handle/10/16980
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv Text
dc.publisher.none.fl_str_mv Universidade Federal do Espírito Santo
Mestrado em Ciências Fisiológicas
dc.publisher.program.fl_str_mv Programa de Pós-Graduação em Ciências Fisiológicas
dc.publisher.initials.fl_str_mv UFES
dc.publisher.country.fl_str_mv BR
dc.publisher.department.fl_str_mv Centro de Ciências da Saúde
publisher.none.fl_str_mv Universidade Federal do Espírito Santo
Mestrado em Ciências Fisiológicas
dc.source.none.fl_str_mv reponame:Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
instname:Universidade Federal do Espírito Santo (UFES)
instacron:UFES
instname_str Universidade Federal do Espírito Santo (UFES)
instacron_str UFES
institution UFES
reponame_str Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
collection Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
bitstream.url.fl_str_mv http://repositorio.ufes.br/bitstreams/8ebf2879-a972-4c3a-897c-a9f6d43e9c52/download
bitstream.checksum.fl_str_mv 4ffcf98b029a8ecf99ae5b53a6f77483
bitstream.checksumAlgorithm.fl_str_mv MD5
repository.name.fl_str_mv Repositório Institucional da Universidade Federal do Espírito Santo (riUfes) - Universidade Federal do Espírito Santo (UFES)
repository.mail.fl_str_mv
_version_ 1813022543783657472